ASH 2021 | Gilteritinib plus azacitidine versus azacitidine monotherapy for newly diagnosed FLT3-mutated AML
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, shares some updates from the Phase III LACEWING trial (NCT02752035), which compared the use of gilteritinib plus azacitidine versus azacitidine alone in patients with newly diagnosed acute myeloid leukemia (AML) with FLT3 mutation ineligible for intensive chemotherapy. Dr Wang explains the aim of this study, which was to see if the addition of gilteritinib would add any benefit or toxicity to azacitidine monotherapy. Dr Wang then discusses the results of this trial, including overall survival (OS), complete remission (CR), and safety signals, and concludes by emphasizing the importance of further investigating this drug combination in this patient population. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
